HC Wainwright Has Positive Outlook for REGENXBIO Q1 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for REGENXBIO in a research report issued to clients and investors on Monday, March 17th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings of ($1.21) per share for the quarter, up from their prior forecast of ($1.35). HC Wainwright currently has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research note on Friday, March 14th. Finally, Morgan Stanley raised their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $8.50 on Wednesday. The company has a market cap of $421.13 million, a price-to-earnings ratio of -1.69 and a beta of 1.35. The stock’s fifty day moving average price is $7.28 and its two-hundred day moving average price is $8.93. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $23.14.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million.

Hedge Funds Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the period. Millennium Management LLC lifted its stake in REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock valued at $10,222,000 after buying an additional 1,061,187 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $3,865,000. Norges Bank bought a new stake in shares of REGENXBIO during the fourth quarter worth $3,474,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of REGENXBIO during the fourth quarter worth $2,793,000. 88.08% of the stock is owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.